N-Acetyl Selank Clinical Use (Russia)

What It Is

N-Acetyl Selank is a chemically modified analog of Selank — a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s under Nikolai F. Myasoedov. Selank itself is the product of extending the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg; amino-acid fragment 289–292 of the IgG heavy chain) with a stabilizing C-terminal Pro-Gly-Pro tail. That extension yields the Thr-Lys-Pro-Arg-Pro-Gly-Pro sequence — a heptapeptide with dramatically improved resistance to aminopeptidase degradation and a substantially longer duration of action than native tuftsin, while preserving its immunomodulatory and anxiolytic profile.

The "N-Acetyl" modification layers two further stabilizing changes on top of Selank's own stabilization strategy. The N-terminus is capped with an acetyl group (which blocks the free alpha-amine from attack by aminopeptidases), and the C-terminus is converted from the free carboxylic acid to a carboxamide (-NH₂) via amidation. Both modifications are standard medicinal-chemistry strategies used to raise serum and mucosal stability of short peptides; the same strategy was used to produce N-Acetyl Semax (see Adamax) from parent Semax. The net effect on N-Acetyl Selank, extrapolating from analogous systems, is a longer mucosal residence time after intranasal dosing, slower enzymatic clearance, and an extended window of receptor engagement at equivalent molar doses.

Selank itself is registered and prescribed in Russia under the trade name Selank for generalized anxiety disorder (GAD), adaptation disorders, and neurasthenia. It has not been approved by the FDA, EMA, MHRA, TGA, or any other non-Russian regulator. The N-acetyl amide analog — the molecule on this page — has no regulatory approval anywhere in the world. It is a research-chemical enhancement of the Russian-approved parent and is sold exclusively through research-peptide channels.

For the rest of this page, claims specific to Selank (the Russian-approved parent) are labeled as such; claims specific to N-Acetyl Selank (the stabilized analog) are labeled separately. Conflating the two is a common error in community literature.

Mechanism of Action

Selank's pharmacology is multimodal. The N-acetyl amide modification does not change the fundamental mechanism — it simply extends the duration over which the same mechanisms act. The following describe the mechanism of the active pharmacophore, which is shared between Selank and N-Acetyl Selank:

• GABAergic allosteric modulation — Selank changes the binding of tritiated GABA to rat brain membranes (V'Yunova 2014) and significantly alters the expression of GABAergic-system genes in the frontal cortex after intranasal dosing (Volkova 2016, Front Pharmacol 7:31). The currently accepted molecular model is that Selank acts as an allosteric modulator of GABA_A receptor signaling rather than as a direct orthosteric ligand — a mechanism that explains why it produces anxiolysis comparable to benzodiazepines but without the GABA_A-α1-subunit-driven sedation and without benzodiazepine-class tolerance / dependence (Kozlovskaya 2003).
• Serotonin metabolism modulation — Semenova and colleagues (2009) reported Selank-induced changes in brain serotonin metabolism in rats pretreated with para-chlorophenylalanine (PCPA), consistent with a serotonin-pathway contribution to the anxiolytic / antidepressant signal beyond pure GABAergic modulation.
• BDNF upregulation in hippocampus — Intranasal Selank elevates BDNF (brain-derived neurotrophic factor) expression in rat hippocampus (Inozemtseva et al., Dokl Biol Sci 2008). BDNF is a central mediator of adult hippocampal neurogenesis, synaptic plasticity, and cognitive resilience to chronic stress; this limb of Selank's mechanism distinguishes it from classical anxiolytics and provides a plausible nootropic / memory-supportive substrate.
• Enkephalinase inhibition — Selank (and its close relative Semax) inhibits enkephalin-degrading enzymes from human serum (Kost 2001). By extending the half-life of endogenous enkephalins, Selank enhances basal opioidergic tone without engaging mu-opioid agonism itself — a mechanism that may contribute to mood stabilization and to its favorable dependence / tolerance profile.
• Immune / interferon induction — Tuftsin is a natural macrophage-activating peptide; Selank retains part of that profile. Uchakina and colleagues (2008) and Ershov and colleagues (PMID 19882898; 2009) documented antiviral activity of Selank against influenza A (H3N2) in vitro and in vivo, associated with induction of interferon-alpha gene expression. Later work extended the antiviral profile to herpes simplex and cytomegalovirus in culture systems.
• Inflammation-related gene expression — Kolomin and colleagues (2013) mapped Selank-induced changes in inflammation-related gene expression in rat spleen and hippocampus, suggesting peripheral and central immunomodulatory pathways that may support stress resilience.
• Enhanced pharmacokinetics via acetyl/amide capping — Specific to N-Acetyl Selank: the modifications slow aminopeptidase and carboxypeptidase cleavage of the terminal residues, the rate-limiting enzymatic clearance steps for native Selank. The result is a longer nasal-mucosal residence, a higher AUC per equivalent molar dose, and an extended window of CNS activity.
• HPA-axis context — Parent Selank lacks direct HPA-axis activation despite its anti-stress framing — a distinguishing feature from endogenous CRH / ACTH physiology. Its anxiolytic and stress-adaptive signature is built on GABAergic / serotonergic / BDNF modulation rather than cortisol suppression or glucocorticoid-receptor engagement.
• Species cross-reactivity — The Russian research program largely characterized Selank in rat and mouse models with intranasal and intraperitoneal administration. Translation to human pharmacology assumes conservation of the GABA_A-allosteric and BDNF-upregulation mechanisms across mammalian species, which is a reasonable but not formally verified assumption.
• Nasal-to-brain delivery advantage — Intranasal administration bypasses first-pass hepatic metabolism and delivers a fraction of the dose along olfactory-nerve and trigeminal-nerve routes directly into the CNS, avoiding BBB-related pharmacokinetic losses that would otherwise limit a hydrophilic peptide. This is the standard delivery route for both parent Selank (Russian nasal spray) and the stabilized analog.

What the Research Shows

All interpretable efficacy data comes from the parent Selank molecule. The N-acetyl amide analog has preclinical pharmacology but no published clinical trials. Read this section with that qualifier.

• Generalized anxiety disorder (Zozulia 2008, PMID 18454096) — The published pivotal clinical study by Zozulia, Neznamov, Siuniakov and colleagues evaluated intranasal Selank in patients with GAD and neurasthenia. Selank showed anxiolytic efficacy comparable to medazepam (a benzodiazepine) without the sedative or amnestic profile of the comparator, and without the typical benzodiazepine dependence / tolerance signature. This study forms the pharmacoregulatory basis for the parent compound's Russian indication.
• Selank vs diazepam (preclinical synergy) — Medvedev et al. (2017) demonstrated that Selank enhances the anxiolytic effect of diazepam in an unpredictable-chronic-mild-stress rat model at a sub-threshold diazepam dose, supporting the allosteric GABA_A-modulator interpretation of its mechanism.
• Immune / antiviral signal — Ershov et al. (PMID 19882898) demonstrated antiviral activity of Selank against influenza A/Aichi/2/68 (H3N2) in vitro and in vivo. Selank induced interferon-alpha gene expression without altering IL-4, IL-10, or TNF-alpha. Field reports from Russian influenza prophylaxis programs describe intranasal Selank administration during seasonal influenza outbreaks.
• GABAergic gene-expression signature (Volkova 2016) — Published in Frontiers in Pharmacology (Front Pharmacol 7:31), this study demonstrated significant changes in the expression of genes involved in GABAergic neurotransmission in rat frontal cortex after Selank administration. This is the cleanest molecular-level evidence for the "allosteric GABA_A" mechanism claim.
• BDNF upregulation in hippocampus (Inozemtseva 2008) — Intranasal Selank elevated hippocampal BDNF expression in rats, providing the preclinical substrate for claimed nootropic effects.
• Enkephalinase inhibition (Kost 2001) — Semax and Selank both inhibit enkephalin-degrading enzymes in human serum, proposed as a shared mechanism behind their mood-stabilizing and anti-stress effects.
• Behavioral / active-avoidance effects (Kozlovskii & Danchev 2002) — Selank produces optimizing effects on active-avoidance conditioning in rats, an effect pattern consistent with its clinical use in anxiety-mediated cognitive impairment.
• N-Acetyl modification rationale — Rationale inferred from medicinal-chemistry literature on terminal capping of small peptides (reduced aminopeptidase / carboxypeptidase susceptibility) and from analogy to the N-Acetyl Semax stabilization program. Direct pharmacokinetic data on N-Acetyl Selank specifically is limited and unpublished in peer-reviewed literature.

Human Data

• Zozulia 2008 (PMID 18454096) — Russian-language clinical study of intranasal Selank in generalized anxiety disorder and neurasthenia. Selank showed anxiolytic efficacy comparable to medazepam without sedative, amnestic, or dependence profile. Published in Zhurnal Nevrologii i Psikhiatrii.
• Ershov 2009 (PMID 19882898) — Selank antiviral activity against influenza A/Aichi/2/68 (H3N2) in cell culture and in vivo mouse infection model, with induction of interferon-alpha gene expression.
• Volkova 2016 (PMID 26924986; Front Pharmacol 7:31) — Selank-induced changes in GABAergic-system gene expression in rat frontal cortex; mechanistic support for allosteric GABA_A modulator interpretation.
• Inozemtseva 2008 (Dokl Biol Sci 421:241-243) — Intranasal Selank regulates BDNF expression in rat hippocampus.
• Kost 2001 (Bioorg Khim 27:180-183) — Semax and Selank inhibit enkephalin-degrading enzymes from human serum.
• Medvedev 2017 — Selank enhances the anxiolytic effect of diazepam in a UCMS rat anxiety model (PMC5322660).
• Kozlovskaya 2003 — Selank and short tuftsin-family peptides in the regulation of adaptive behavior in stress; mechanistic behavioral pharmacology review.
• Uchakina 2008 — Selank-induced cytokine shifts and interferon induction in human leukocyte cultures; immunomodulatory signature extended beyond antiviral context.
• Kolomin 2013 — Temporary dynamics of inflammation-related gene expression under Selank action in rat spleen and hippocampus.
• Semenova 2009 — Comparison of Selank and tuftsin effects on brain serotonin metabolism in PCPA-pretreated rats.

There are no published human clinical trials specifically of N-Acetyl Selank (the stabilized analog). All positive human data belongs to the parent compound Selank.

Dosing from the Literature

Russian clinical practice with parent Selank uses a 0.15% nasal-spray formulation delivering approximately 300 mcg per spray (3 drops / one spray per nostril). The ranges below summarize that clinical range plus the community-use range for the stabilized N-acetyl analog.

Reconstitution & Storage

N-Acetyl Selank is supplied as a lyophilized powder, typically 5 mg or 10 mg per vial. It is formulated for intranasal delivery. A bacteriostatic-water-based nasal spray is the most common administration vehicle.

• Reconstitution technique — Add diluent slowly down the side of the vial; swirl gently to dissolve. Do not shake aggressively.
• Nasal spray filling — Transfer reconstituted solution into a clean, calibrated nasal spray bottle. Measure spray volume before first use (typically 50–100 µL per actuation) to calculate per-dose mcg.
• Storage (lyophilized) — Refrigerated 2–8°C; stable 18–24 months. Protect from light.
• Storage (reconstituted) — Refrigerated 2–8°C for up to 21–28 days when reconstituted with BAC water. Discard if cloudiness or discoloration develops.
• Do not freeze reconstituted solution.

→ Use the Kalios Dosing Calculator for N-Acetyl Selank reconstitution

Side Effects & Risks

• Generally very well-tolerated — Parent Selank has decades of clinical use in Russia with a favorable safety profile. No sedation, no amnestic effect, and no reported benzodiazepine-class withdrawal syndrome.
• Nasal irritation — Mild stinging, transient nasal dryness, or rhinorrhea at the application site. Usually self-limiting; switching spray vehicles can help.
• Headache — Occasional; typically mild and dose-related.
• Transient fatigue — Some users report mild drowsiness early in a course; distinct from benzodiazepine sedation and usually does not affect cognition.
• Paradoxical anxiety (rare) — A minority of users report heightened alertness that crosses into anxiety at the upper end of community dose ranges. Reduce dose.
• Immune-related considerations — Selank induces interferon-alpha in preclinical models. Users with autoimmune or inflammatory disease should consult a physician before use; interferon-alpha has known associations with autoimmune phenomena in therapeutic contexts.
• No dependence or withdrawal — Russian clinical data does not report benzodiazepine-class dependence with parent Selank. Analog data is extrapolated.
• Contraindications — Pregnancy and lactation (insufficient data). Active autoimmune disease should be discussed with a physician. Concurrent monoamine oxidase inhibitor therapy — interaction risk is theoretical.
• Purity / source considerations — As with all research peptides, N-Acetyl Selank sold through unregulated channels can vary in identity and purity. This is a source of adverse-event heterogeneity in community reports.
• Long-term safety of stabilized analog — Not characterized. Parent Selank has decades of human data; N-Acetyl Selank does not.

Bloodwork & Monitoring

• Comprehensive metabolic panel (CMP) — Baseline; repeat every 6–12 months for long-term users. Standard renal and hepatic screening; no Selank-specific abnormalities expected.
• Complete blood count (CBC) — Baseline; repeat every 6–12 months. Preclinical immunomodulatory signal warrants surveillance.
• Anxiety scale (e.g., GAD-7, HAM-A) — Formal baseline and post-course scoring is the cleanest way to detect clinically meaningful response vs expectancy.
• Sleep and stimulant panel — If concurrent caffeine or stimulant use is substantial, monitor subjectively; Selank may shift the felt balance.
• Autoimmune screening — If family or personal history of autoimmune disease, baseline ANA and TSH / thyroid panel are reasonable given interferon-related mechanism.
• Not a substitute for a psychiatric evaluation — Anyone considering Selank or N-Acetyl Selank for anxiety should first have a formal psychiatric evaluation with a licensed provider. Untreated anxiety disorders benefit from established, evidence-based psychiatric and psychological care.
• Medication reconciliation — Document all current psychiatric, benzodiazepine, SSRI, SNRI, and stimulant medications before initiating. Interactions with validated anxiolytics have not been formally mapped for the N-acetyl analog.
• Autonomic tracking — If subjective anxiolysis is the target, heart-rate variability (HRV) tracking from a consumer wearable provides an objective adjunct to symptom scales.

None of this monitoring substitutes for a supervised psychiatric care plan in patients with clinically significant anxiety, depression, or co-occurring psychiatric disorders. N-Acetyl Selank is at best an adjunct to validated care — never a first-line replacement for evidence-based anxiolytic pharmacotherapy or psychotherapy.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Supportive Nutrition & Lifestyle

Anxiolytic and nootropic peptides work best layered on top of validated lifestyle levers. Users considering N-Acetyl Selank should not view it as a substitute for the following foundational inputs:

• Sleep (7–9 hours consolidated) — The single largest anxiolytic lever available to any individual. GABAergic tone, HPA-axis regulation, and serotonergic recovery all depend on adequate sleep; chronic sleep restriction undercuts every pharmacologic anxiolytic including Selank-family peptides.
• Aerobic exercise (150+ minutes/week) — Direct BDNF upregulation (the same mechanism Selank engages) plus durable anxiolytic effect in RCT evidence comparable to SSRIs for mild-to-moderate anxiety. Highest-leverage non-pharmacologic intervention.
• Cognitive-behavioral therapy / exposure-based therapy — Evidence-based first-line treatment for anxiety disorders. Selank / N-Acetyl Selank would at best be an adjunct, not a replacement, for validated therapy.
• Alcohol reduction — Chronic alcohol dysregulates GABAergic tone; users pursuing GABA-axis pharmacologic support should reduce alcohol intake to maximize responsiveness.
• Caffeine moderation — Excess caffeine drives sympathetic activation that can mask or overwhelm Selank's anxiolytic signal. Titrate caffeine before evaluating any anxiolytic peptide.
• Magnesium (glycinate 200–400 mg or L-threonate 1,000–2,000 mg) — Foundational GABA-system nutritional support; complements Selank's GABA_A-allosteric mechanism without pharmacodynamic overlap.
• Omega-3 (2–3 g EPA/DHA) — Membrane fluidity and neuroinflammation support; modest anxiolytic RCT evidence.
• L-theanine (100–200 mg) — Mild GABA-potentiating amino acid; benign safety profile and complementary to Selank's mechanism.
• B-complex (methylated forms) — Supporting methylation-dependent monoamine synthesis; mood and anxiety correlate with B-vitamin status.
• Breathwork and vagal-tone practices — Box-breathing, resonance breathing, HRV-biofeedback training — direct parasympathetic-activation tools that complement pharmacologic anxiolysis.

What to Expect — Timeline

Subjective effects of N-Acetyl Selank vary substantially by baseline anxiety burden and dose. The following synthesizes Russian clinical practice with parent Selank and community reports with the stabilized analog.

• First dose (within 30–60 minutes) — Subtle shift toward calm focus. Some users report a cognitive "clearing" effect without sedation; others note no acute change. First-dose response is the weakest predictor of course-level response.
• Days 1–3 — Acute anxiolytic effect gradually consolidates. GABA_A allosteric modulation has reached near-steady state in CNS; BDNF upregulation is still building.
• Week 1 — Classical Russian-practice response window; users reporting benefit typically identify it by the end of week 1.
• Weeks 2–3 — Maximal course-level benefit. Parent-Selank courses in Russian outpatient practice typically run 10–14 days; the stabilized analog's extended half-life may support shorter or less-frequent dosing for equivalent benefit.
• After course cessation — Effect gradually wanes over 1–3 weeks as CNS tone returns to baseline. Unlike benzodiazepines, no withdrawal syndrome or rebound anxiety characterizes Selank discontinuation in Russian clinical experience.
• Non-responders — Real. A meaningful minority of users report no subjective effect on standard-dose Selank family peptides. Dose-response in this population is unpredictable and often unresponsive to dose escalation.
• Typical course cycling — Khavinson-era Russian practice rotates Selank / Semax courses with rest periods of 2–4 weeks; the analog's enhanced pharmacokinetics may permit longer between-course intervals, though this is community practice rather than validated protocol.
• If you feel worse — Paradoxical anxiogenic response, persistent headache, nasal irritation that doesn't resolve, or any unusual symptom — stop and evaluate. Consider product-purity verification.

Regulatory Status

Related Compounds

People researching N-Acetyl Selank often also look at these:

Next Steps

Key References

1. Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OIu, Serebriakova EV, Siranchieva OA, Andriushenko AV, Telesheva ES, Siuniakov SA, Smulevich AB, Miasoedov NF, Seredenin SB. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096.
2. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016 Feb 18;7:31. PMID: 26924986.
3. Ershov FI, Uchakin PN, Uchakina ON, Mezentseva MV, Alekseeva LA, Miasoedov NF. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009;54(5):19-24. PMID: 19882898.
4. Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841774.
5. Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, Zozulia AA. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180-183. PMID: 11443939.
6. Medvedev VE, Tereshchenko OV, Kost NV, Ter-Israelyan AY, Gushanskaya EV, Chobanu IK, Sokolov OY, Miasoedov NF. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. PMC5322660.
7. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neurosci Med. 2013;4(4):223-252.
8. Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(9):853-860. PMID: 14969428.
9. Seredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskii II, Semenova TP, Czabak-Garbacz R. The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction. Zh Vyssh Nerv Deiat Im I P Pavlova. 1998;48(1):153-160. PMID: 9612605.
10. Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide selank on an active avoidance reflex in rats. Zh Vyssh Nerv Deiat Im I P Pavlova. 2002;52(5):579-584. PMID: 12449037.
11. Semenova TP, Kozlovskii II, Zakharova NM, Kozlovskaia MM. Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA. Eksp Klin Farmakol. 2009;72(4):6-8. PMID: 19803388.
12. Kolomin T, Morozova M, Volkova A, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50-55. PMID: 24275703.
13. Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. PMID: 18577925.
14. Andreeva LA, Nagaev IY, Mezentseva MV, Shapoval IM, Podchernyaeva RY, Shcherbenko VE, Potapova LA, Rusakova EV, Miasoedov NF. Antiviral properties of structural fragments of the peptide Selank. Dokl Biol Sci. 2010;431:86-88. PMID: 20506848.